Anthony El-Khoueiry, MD:The question is, “What makes a patient a good resection candidate?” I would start by saying that the 2 curative modalities that are established in the treatment of hepatocellular carcinoma are liver transplantation and surgical resection. Given the limited supply of organs, and given the long-term impact of having a liver transplant, surgical resection remains a very viable option for patients.
However, surgical resection is limited by various factors. The main limitation to surgical resection is the availability of, or the amount of, residual liver that will be left behind that is healthy enough to sustain life. So, having advanced cirrhosis, or having significant portal hypertension, will preclude the patient from having surgical resection. In other words, the patient has to have well-preserved liver functiongenerally, Child-Pugh grade A cirrhosis with limited or no signs of portal hypertension. So, depending on the institution, things like a normal bilirubin level may be regarded as a requirement for resection; a platelet count that’s within the normal range or above 100,000 would be a requirement; and the absence of glaring signs of portal hypertension, such as esophageal varices, would be a requirement.
Another limitation to surgical resection is the size of the tumor and its relationship to blood vessels in the liver. These are technical decisions that have to be made by an experienced surgeon to determine whether or not it would be appropriate to do a resection, and not affect vital vasculature in the liver. A third limitation is whether or not there is vascular invasion. So, if the hepatocellular carcinoma invades the portal vein or the inferior vena cava, these are thought to be poor prognostic markers, and the outcomes after surgical resection would be poor. These patients are usually not sent for surgical resection.
Now there are some relative contraindications, but these, again, are relative and depend on institutional practice, the context, and the availability of other treatment options. Having multifocal disease is also considered a relative contraindication to surgical resection, because the risk of recurrence increases with the increasing number of lesions in the liver.
Transcript edited for clarity.
February 2014
August 2016
April 2017
FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC
September 24th 2024A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.
Read More
FDA Supports Phase 3 Plan for Amezalpat in Hepatocellular Carcinoma
August 16th 2024The FDA has given positive feedback on the planned phase 3 study for the combination of amezalpat, atezolizumab, and bevacizumab in the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Read More